Cite
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
MLA
Gallego, A., et al. “Bevacizumab in Recurrent Ovarian Cancer: Could It Be Particularly Effective in Patients with Clear Cell Carcinoma?” Clinical & Translational Oncology, vol. 23, no. 3, Mar. 2021, pp. 536–42. EBSCOhost, https://doi.org/10.1007/s12094-020-02446-z.
APA
Gallego, A., Ramon-Patino, J., Brenes, J., Mendiola, M., Berjon, A., Casado, G., Castelo, B., Espinosa, E., Hernandez, A., Hardisson, D., Feliu, J., & Redondo, A. (2021). Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma? Clinical & Translational Oncology, 23(3), 536–542. https://doi.org/10.1007/s12094-020-02446-z
Chicago
Gallego, A., J. Ramon-Patino, J. Brenes, M. Mendiola, A. Berjon, G. Casado, B. Castelo, et al. 2021. “Bevacizumab in Recurrent Ovarian Cancer: Could It Be Particularly Effective in Patients with Clear Cell Carcinoma?” Clinical & Translational Oncology 23 (3): 536–42. doi:10.1007/s12094-020-02446-z.